Percentage of patients receiving concomitant asthma medications by drug class (all extension patients)
| Drug class | Omalizumab | Placebo |
| Subjects n | 254 | 229 |
| Inhaled corticosteroids | 64.6 | 84.7 |
| Fluticasone propionate | 0.8 | 2.2 |
| Budesonide | 0.0 | 1.3 |
| Long acting β2‐agonists | 11.0 | 17.0 |
| Salmeterol hydroxynaphthoate | 5.9 | 11.4 |
| Formoterol fumarate# | 4.7 | 5.7 |
| Leukotriene inhibitors and antagonists | 0.4 | 3.5 |
| Xanthines | 0.4 | 0.0 |
Data are presented as %
#: formoterol not marketed in USA